US 12,312,399 B2
Methods and compositions comprising purified recombinant polypeptides
X. Christopher Yu, Piedmont, CA (US); Susan C. Fisher, San Carlos, CA (US); Ailen M. Sanchez, Foster City, CA (US); and Martin Vanderlaan, San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Apr. 21, 2023, as Appl. No. 18/304,936.
Application 18/304,936 is a continuation of application No. 17/031,468, filed on Sep. 24, 2020, granted, now 11,667,706.
Application 17/031,468 is a continuation of application No. 15/902,145, filed on Feb. 22, 2018, granted, now 10,822,404, issued on Nov. 3, 2020.
Application 15/902,145 is a continuation of application No. 15/065,693, filed on Mar. 9, 2016, granted, now 9,920,120, issued on Mar. 20, 2018.
Application 15/065,693 is a continuation of application No. PCT/US2014/055387, filed on Sep. 12, 2014.
Claims priority of provisional application 61/877,517, filed on Sep. 13, 2013.
Prior Publication US 2023/0250165 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); C07K 1/18 (2006.01); C07K 1/22 (2006.01); C07K 1/36 (2006.01); C07K 16/06 (2006.01); C07K 16/08 (2006.01); C07K 16/18 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [C07K 1/18 (2013.01); C07K 1/22 (2013.01); C07K 1/36 (2013.01); C07K 16/065 (2013.01); C07K 16/089 (2023.08); C07K 16/18 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01)] 10 Claims
 
1. A composition comprising an anti-IL13 monoclonal antibody purified from Chinese hamster ovary host cells and less than 20 ng/mg of hamster phospholipase B-like 2 (PLBL2), wherein the anti-IL13 antibody comprises three heavy chain CDRs, CDR-H1 having the amino acid sequence of SEQ ID NO: 1, CDR-H2 having the amino acid sequence of SEQ ID NO: 2, and CDR-H3 having the amino acid sequence of SEQ ID NO: 3, and three light chain CDRs, CDR-L1 having the amino acid sequence of SEQ ID NO: 4, CDR-L2 having the amino acid sequence of SEQ ID NO: 5, and CDR-L3 having the amino acid sequence of SEQ ID NO: 6.